RxDoctor Payments Data

Robin Boone, NP

Nurse Practitioner · Greensboro, NCNPI 1013364447

Payments from drug & device makers

$1,627in general payments, 2019–2025

Across 58 payments — averaging $28.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$669
  • Indivior Inc.$348
  • Braeburn Inc.$243
  • Alkermes, Inc.$199
  • AbbVie$149
  • Orexo US, Inc.$18

What the payments were for

  • Food & beverage$1,59798%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead24$669
Indivior Inc.13$348
Braeburn Inc.8$243
Alkermes, Inc.6$199
AbbVie6$149
Orexo US, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,627 in reported general payments places this provider in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$56,470
Medicare patients
61
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SublocadeBuprenorphine46$95,009
SuboxoneBuprenorphine Hcl/Naloxone Hcl127$42,590
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl446$40,284
ZubsolvBuprenorphine Hcl/Naloxone Hcl32$7,826
Naloxone Hcl11$720
Buprenorphine Hcl23$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade, Suboxone$348$137,599173 claims
Orexo US, Inc.Zubsolv$18$7,82632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →